Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
Dual GIP/GLP-1 Agonist
Evidence Grade: A (FDA-Approved Analog)
Tirzepatide Protocol Guide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist researched for metabolic regulation and body composition. It is the first dual incretin agonist, offering a unique mechanism of action. This protocol covers titrated dosing from 2.5mg to 15mg weekly, reconstitution, subcutaneous administration, expected timelines, and monitoring guidelines.
Protocol Overview
- Compound
- Tirzepatide
- Category
- Dual GIP/GLP-1 Receptor Agonist
- Mechanism
- Activates both GIP and GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via dual incretin pathways
- Molecular Weight
- 4,813.45 Da
- Half-Life
- ~5 days (120 hours)
- Vial Size
- 5mg lyophilized powder
- Route
- Subcutaneous injection
- Frequency
- Once weekly
- Cycle Length
- 20-24+ weeks (with titration)
Dosing Protocol
Tirzepatide uses a gradual titration to minimize GI side effects. Each dose level is maintained for at least 4 weeks.
| Phase | Weeks | Dose | Frequency | Route |
|---|---|---|---|---|
| Titration 1 | 1-4 | 2.5 mg | Once weekly | Subcutaneous |
| Titration 2 | 5-8 | 5.0 mg | Once weekly | Subcutaneous |
| Titration 3 | 9-12 | 7.5 mg | Once weekly | Subcutaneous |
| Titration 4 | 13-16 | 10 mg | Once weekly | Subcutaneous |
| Titration 5 | 17-20 | 12.5 mg | Once weekly | Subcutaneous |
| Maintenance | 21+ | 15 mg | Once weekly | Subcutaneous |
Note: Many research subjects achieve desired outcomes at 5-10mg without needing maximum dose. Titrate based on tolerability.
Reconstitution Instructions
Materials Needed
- Tirzepatide 5mg lyophilized vial
- Bacteriostatic water (BAC water)
- 3mL syringe with 18-20ga needle (reconstitution)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol swab
- Draw 1mL bacteriostatic water into syringe
- Slowly inject water down the vial wall
- Gently swirl until fully dissolved (do not shake)
- Allow 5-10 minutes for complete dissolution
- Final concentration: 5 mg/mL (0.5mg per 10 units)
| Dose | Volume (1mL recon) | Insulin Syringe Units |
|---|---|---|
| 2.5 mg | 0.50 mL | 50 units |
| 5.0 mg | 1.00 mL (full vial) | 100 units |
Tip: For higher doses, use multiple vials or reconstitute with less water for higher concentration. For 10mg+ doses, reconstitute a 10mg vial or draw from two 5mg vials.
Administration Guide
Injection Sites
- Abdomen: 2+ inches from navel (preferred)
- Thigh: Front/outer middle third
- Upper arm: Back of arm
Rotate sites weekly to prevent lipodystrophy.
Timing & Storage
- Day/Time: Same day each week, any time
- With food: Regardless of meal timing
- Storage (unreconstituted): Refrigerate 2-8°C
- Storage (reconstituted): Refrigerate, use within 28 days
Expected Timeline
Week 1-4
Initial adaptation at 2.5mg. Mild appetite changes. Some GI adjustment (nausea, mild bloating). Body adjusting to dual incretin activation.
Week 5-8
At 5mg, more pronounced appetite suppression. Early metabolic marker improvements. Clinical trials showed measurable HbA1c reduction by this point.
Week 9-12
Significant appetite regulation. Body composition changes become visible. Lipid panel improvements often observed.
Week 13-20
Higher doses (10-12.5mg) provide peak metabolic effects. SURMOUNT trials showed average 20%+ body weight reduction. Sustained glycemic improvements.
Week 20+
Maximum dose (15mg) for those who tolerate. Ongoing body composition optimization. Cardiovascular biomarker benefits continue to accumulate.
Side Effects & Monitoring
Common Side Effects
- Nausea (most common, usually transient)
- Diarrhea or constipation
- Decreased appetite
- Injection site reactions
- Dyspepsia / heartburn
- Fatigue during titration
Serious Concerns
- Severe abdominal pain (pancreatitis risk)
- Allergic reactions
- Hypoglycemia (especially with insulin)
- Gallbladder issues
- Thyroid C-cell tumor risk (preclinical)
- Vision changes (diabetic retinopathy)
Stacking Recommendations
Compatible Compounds
- BPC-157: GI protection during titration
- Tesamorelin: Complementary visceral fat reduction
- MOTS-C: Mitochondrial metabolic support
- L-Carnitine: Fat oxidation support
- NAD+: Cellular energy and metabolism
Stacking Notes
- Do NOT combine with other GLP-1 agonists (semaglutide, liraglutide)
- Monitor glucose closely if stacking with insulin-sensitizers
- Ensure high protein intake (1g/lb lean mass) to preserve muscle
- Consider creatine supplementation for lean mass preservation
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Metabolic | Fasting glucose, HbA1c, fasting insulin, HOMA-IR | Baseline, Week 4, 8, 16 |
| Lipids | Total cholesterol, LDL, HDL, triglycerides, ApoB | Baseline, Week 8, 16 |
| Liver | ALT, AST, GGT, bilirubin | Baseline, Week 8 |
| Kidney | BUN, creatinine, eGFR | Baseline, Week 8 |
| Pancreatic | Amylase, lipase | Baseline, Week 4, 12 |
| Thyroid | TSH, free T3, free T4 | Baseline, Week 12 |
Related Tools & Resources
📖 Encyclopedia Article
Tirzepatide — Complete Research Guide
Mechanism of action, clinical evidence, pharmacokinetics, regulatory status & references
Read Article →
Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Paid partnership · Learn more